AMRING PHARMS
GenericsAMRING PHARMS is a generic drug manufacturer focused on Ophthalmology, Infectious Disease, Dermatology.
AMRING PHARMS's Key Drugs
AMRING PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AMRING PHARMS's Recent FDA Approvals
New NDA/BLA approvals for AMRING PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
AMRING PHARMS's Therapeutic Areas
AMRING PHARMS's approved drugs and pipeline span 3 therapeutic areas, led by Ophthalmology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AMRING PHARMS's Top Competitors
AMRING PHARMS's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, BAUSCH AND LOMB INC, and FOUGERA PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AMRING PHARMS Pipeline Snapshot
Active clinical trials for AMRING PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2008-01-16
- Latest
- 2021-08-23
- Applications
- 4